In June, FibroGen whiffed twice with a pair of its phase 3 clinical trials, and canceled a third phase 3 trial for IPF that was expected to also fail. The bottom line with those trials was simply that ...

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of ...

FibroGen says the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial. FibroGen also announces a clinical trial supply agreement with Regeneron Pharmaceuticals.

(Reuters) -FibroGen Inc's treatment for patients with a muscle-wasting disorder that typically binds them to a wheelchair failed to improve measures of upper limb strength, sending the drug ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...

The stock price of FibroGen (NASDAQ: FGEN), a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a large ...

Fibrogen presented new clinical trial data on Friday that alleviates concerns about the heart safety of its experimental anemia pill, the drugmaker said. A pooled safety analysis of approximately ...